FDA widens holds on immunotherapy combination blood cancer trials – Reuters
Reuters |
FDA widens holds on immunotherapy combination blood cancer trials
Reuters (Reuters) – U.S. health regulators stopped five blood cancer trials testing AstraZeneca Plc's immunotherapy Imfinzi in combination with Celgene Corp medicines from accepting new patients and halted another study entirely, the companies said on Thursday. Pharmalittle: FDA places hold on Celgene and Bristol trials; AstraZeneca-Amgen asthma drug looks strong |
